BridgeBio has substantially improved the course of the novel therapy for cardiac amyloidosis, employing the investigational drug. Early clinical data suggests significant benefits for individuals suffering with the https://biotech972084.arwebo.com/64711109/company-advances-cardiac-amyloidosis-treatment-using-the-therapy